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Abstract
Background:  Mutations altering BLM function are associated with highly elevated cancer
susceptibility (Bloom syndrome). Thus, genetic variants of BLM and proteins that form complexes
with BLM, such as TOP3A and RMI1, might affect cancer risk as well.
Methods: In this study we have studied 26 tagged single nucleotide polymorphisms (tagSNPs) in
RMI1,  TOP3A, and BLM  and their associations with cancer risk in acute myeloid leukemia/
myelodysplatic syndromes (AML/MDS; N = 152), malignant melanoma (N = 170), and bladder
cancer (N = 61). Two population-based control groups were used (N = 119 and N = 156).
Results: Based on consistency in effect estimates for the three cancer forms and similar allelic
frequencies of the variant alleles in the control groups, two SNPs in TOP3A (rs1563634 and
rs12945597) and two SNPs in BLM (rs401549 and rs2532105) were selected for analysis in breast
cancer cases (N = 200) and a control group recruited from spouses of cancer patients (N = 131).
The rs12945597 in TOP3A and rs2532105 in BLM showed increased risk for breast cancer. We then
combined all cases (N = 584) and controls (N = 406) respectively and found significantly increased
risk for variant carriers of rs1563634 A/G (AG carriers OR = 1.7 [95%CI 1.1–2.6], AA carriers OR
= 1.8 [1.2–2.8]), rs12945597 G/A (GA carriers OR = 1.5 [1.1–1.9], AA carriers OR = 1.6 [1.0–2.5]),
and rs2532105 C/T (CT+TT carriers OR = 1.8 [1.4–2.5]). Gene-gene interaction analysis suggested
an additive effect of carrying more than one risk allele. For the variants of TOP3A, the risk increment
was more pronounced for older carriers.
Conclusion: These results further support a role of low-penetrance genes involved in BLM-
associated homologous recombination for cancer risk.
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Background
Bloom syndrome is a condition characterised by growth
inhibition, light sensitivity, and high incidence of cancer
in early life [1]. Although there appears to be a predomi-
nance of lymphocytic leukemia and lymphoma, many
cancer types are seen in this condition. A defining feature
of Bloom's syndrome is an elevated frequency of sister
chromatide exchanges. These arise from crossing over of
chromatide arms during homologous recombination, a
ubiquitous process that exists to repair DNA double-
stranded breaks and damaged replication forks. Whereas
crossing over is required in meiosis, it can in mitotic cells
be associated with a detrimental loss of heterozygosity, a
common feature in neoplastic cells.
BLM, the helicase mutated in Bloom syndrome, is found
in protein complexes together with topoisomerase IIIa
(TOP3A) and a newly identified member, the RECQ-
mediated genome instabilitity 1 (RMI1) protein, that
process double Holliday junction intermediates into non-
crossover recombinants [2-5]. This dissolution activity of
the BLM-TOP3A-RMI1 complex is thought to be critical
for the suppression of DNA crossover formation in
mitotic cells and cancer avoidance in humans. The com-
plex might process many other DNA structures as well,
such as stalled replication forks [6] and has been impli-
cated in checkpoint signalling and checkpoint responses
during DNA damage [5].
Since mutations that alter BLM function are associated
with elevated cancer susceptibility, we reasoned that
genetic variants of BLM and other proteins that form a
complex with BLM might affect the risk for different can-
cer forms. In order to test this hypothesis we analysed in
this study polymorphisms in the RMI1, TOP3A and BLM,
and their association with cancer risk in available case-
control materials, namely AML/MDSs (acute myeloid
leukemia and myelodysplastic syndromes), malignant
melanoma, and bladder and breast cancer.
Methods
Study populations
The studies have been approved by the Ethics Committee
of Lund University. All study participants gave informed
consent before participation in the study. We did not ask
for ethnicity of the study participants. However, based on
their names, the absolute majority of the participants was
of European descent (predominating Swedish). All cancer
patients were voluntarily recruited from the Southern
Health Care Region of Sweden. Study population charac-
teristics for different cancer forms are shown in Table 1.
The AML/MDS and the malignant melanoma study popu-
lations are described in more detail in Broberg et al. [7]. In
short, the diagnoses were: 78 cases of AMLand, 56 cases of
MDS, and in 18 subjects AML preceeded by a MDS. All the
participating melanoma patients (N = 170) had a primary
cutaneous melanoma diagnosed except for two patients,
who presented with metastatic disease without known
primary site of their melanoma. The AML/MDS patients'
samples were collected during the years 1998–2004 and
the malignant melanoma samples during 2001–2005.
The control group was drawn randomly from the Regional
Population Registry during 2001–2004, frequency
matched with the cases series with respect to sex, year of
birth, as well as country of living. The bladder study
groups have been studied earlier and are described more
in detail in Broberg et al. [8]. The bladder cancer patients'
(N = 61) and the control individuals' samples (N = 156)
(mouth washes) were collected during 1995–2000. The
control group was drawn randomly from the Regional
Population Registry during 1995–2000, frequency
matched with the cases with respect to sex, year of birth,
as well as country of living. The breast cancer patients all
came for treatment at the Oncology Clinic at Lund Univer-
sity Hospital between 1990 and 1998, where they
accepted to participate in the study and donated blood
samples. The case group encompassed 200 patients, all of
which were women. According to the TNM classification,
6 individuals were in stage 0, 79 in stage I, 72 in stage II
and 15 in stage III. Twenty-eight cases could not be classi-
fied, mainly because of no axillary sampling performed
due to locally advanced tumors. The control group con-
sisted of 131 accompanying female spouses to cancer
Table 1: Study characteristics of cases and controls for the different cancer forms.
AML/MDSa Malignant melanoma Bladder cancer Breast cancer
Cases Cases Controls Cases Controls Cases Controls
N 152 170 119 61 156 200 131
Median age (range) 72
(22–95)
66
(24–80)
68
(22–96)
69
(35–85)
69
(21–90)
59
(34–86)
63
(23–85)
Women/Men
(%)
73/79
(48/52)
87/83
(51/49)
53/66
(44.5/55.5)
9/52
(15/85)
34/122
(22/78)
200/0
(100/0)
131/0
(100/0)
a AML/MDS denotes acute myeloid leukemia/myelodysplastic syndromesBMC Cancer 2009, 9:140 http://www.biomedcentral.com/1471-2407/9/140
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patients coming to the Oncology Clinic for treatment,
recruited from Southern Sweden. The control individuals
filled in a questionnaire about their health status and
donated a blood sample. Spouses without former cancer
were selected for the study.
Polymorphism selection and initial screening
Polymorphisms were selected in Bloom syndrome related
genes (RMI1, TOP3A and BLM) from the HapMap data
http://www.hapmap.org. TagSNPs were identified from
the CEU population data (CEPH, Utah residents with
ancestry from northern and western Europe), and by run-
ning the data in Haploview ([9]). The TagSNPs chosen
showed an allelic frequency of at least 10%. DNA extrac-
tions for all samples were made with QIAmp 96 DNA
blood kit (Qiagen, Hilden, Germany) by SWEGENE
resource centre for Profiling Polygenic Diseases in Malmö
University hospital, Sweden, apart from the blood sam-
ples from the breast control group, which were extracted
for DNA with Wizard Genomic DNA Purification Kit
(Promega, Madison, WI, USA). The polymorphisms were
analyzed with matrix-assisted laser desorption/ionization
time-of-flight
(MALDI-TOF) mass spectrometry (Sequenom™, San
Diego, CA) at the SWEGENE resource centre for Profiling
Polygenic Diseases in Malmö University hospital. For the
Sequenom assays, 20 percent of the samples were rerun
and negative controls (water instead of DNA) were
included in each run. Out of 28 tagSNPs analysed, 2 failed
in the analysis, which left us with 26 tagSNPs. The fre-
quency of individuals with missing genotype data ranged
between 1.3%–6.8%/SNP assay for leukaemia and malig-
nant melanoma, and 7.7%–12.7%/SNP assay for bladder
cancer. The drop rate for bladder cancer probably reflects
that there was limited amount of DNA left. We carefully
evaluated the results of each assay and only included
those samples that demonstrated positive signals in most
assays. Selection of tagSNPs for further analysis of the
breast cancer study population was based on changes in
effect estimates (computed as odds ratios, ORs) in the
same direction (reduced or increased risk) in at least two
cancer forms of the three analyzed. Secondly, the allele
frequencies in the two control groups should be similar.
Genotyping of polymorphisms in the breast cancer/control 
material
The genotyping was performed on 200 cases of breast can-
cer and 131 controls. The selected polymorphisms were
rs1563634 and rs12945597 (C__31923586_10) in
TOP3A, rs401549 and rs2532105 in BLM. Taqman assays
and allelic discrimination was run on an ABI PRISM 7000
(Applied Biosystems). The Taqman assay reaction volume
was 25 μl containing: 1× Universal Taqman mix (Applied
Biosystems), each primer at 0.45 μM mixed with each
probe at 0.10 μM, and 5–12 ng of DNA template. The
thermal cycle protocol was 95°C for 10 min, 95°C for 15
sec and 60°C for 1 min (40 cycles). Plate reading for
allelic discrimination was performed under 60°C for 1
min. For all assays, at least 5% of the samples were reana-
lyzed and the concordance rate of these analyses was
100%.
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) test was under-
taken using the chi-square test in the control groups.
Effect estimates were computed as odds ratios (ORs) with
95% confidence intervals (95% CIs) by logistic regression
using SPSS 14.0 (version 14; SPSS, Chicago, IL, USA). For
rs1563634 in TOP3A, the reference category was changed
in Tables 2, 3, 4 and 5 to the variant homozygous geno-
type in order to display cancer risk increment. The analy-
ses were performed both without any adjustments, as well
as with adjustments for sex and age. When stratifying for
age, subjects were categorized into two groups, based on
the median age among the cancer cases and control
groups combined as a cut-off (< 65 and ≥ 65 years). The
stratified analysis was adjusted for sex.
To assess false positives, the False Positive Report Proba-
bility (FPRP) [10] was calculated, based on observed asso-
ciation data, according to the formula; α *(1-π)/(α*(1-π)
+ (1-β)*π), α denotes the p-values from the logistic regres-
sion analyses, 1-β denotes the statistical power for the
tests and π denotes the prior probability of a true associa-
tion of the tested genetic variant and outcome. OR values
above 1.5 were considered as this is a likely threshold
value for important biologic effects [11,12]. The prior
probability employed was set to 0.01 (low probability)
and 0.1 (high probability) for all SNPs. The FPRP treshold
was set to 0.5, thus statistically significant SNPs with a
FPRP above 0.5 were in this study not considered reliable
to classify as true positives. These values, as well as the val-
ues for ORs and 95% CIs were entered into the online
spreadsheet included in Wacholder et al. [10] for FPRP
calculations.
Bioinformatics
SNPs with a statistically significant association were fur-
ther evaluated in silico for potential function. PupaSNP
(http://www.pupasnp.org, [13,14]) was employed in
order to detect SNPs potentially affecting transcription
factor binding sites, exonic splicing enhancers/silencers,
triplexes, splice sites and microRNA target sites. Emboss
CpGPlot http://www.ebi.ac.uk/emboss/cpgplot/ was
employed to detect CpG-rich areas.
Results
All SNPs were in HWE in the control groups for AML/
MDS, malignant melanoma, and bladder cancer. The fourBMC Cancer 2009, 9:140 http://www.biomedcentral.com/1471-2407/9/140
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Table 2: Associations of polymorphisms in A) TOP3A and B) BLM and cancer risk (presented as odds ratios and 95% confidence 
interval) in different cancer forms.a
Cancer type Polymorphism Risk allele %
Cases/controls
Genotype Cases Controls OR 95% CI
AML/MDS TOP3A
rs1563634b
75/66 AA 11 14 1.0c, d -
AG 54 52 1.3 0.53–3.1
GG 84 52 2.0 0.82–4.7
Malignant
melanoma
75/66 AA 12 14 1.0 -
AG 60 52 1.4 0.58–3.2
GG 96 52 2.2 0.93–5.1
Bladder 68/67 AA 3 19 1.0 -
cancer AG 32 54 3.9 1.1–14
GG 25 66 2.5 0.67–9.1
Breast cancer 68/68 AA 19 16 1.0 -
AG 88 48 1.5 0.72–3.2
GG 92 66 1.2 0.57–2.5
AML/MDS TOP3A
rs12945597
37/25 GG 61 64 1.0 -
GA 63 49 1.3 0.76–2.2
AA 22 5 4.9 1.7–14
Malignant
melanoma
32/25 GG 78 64 1.0 -
GA 72 49 1.2 0.74–2.0
AA 18 5 3.0 1.0–8.4
Bladder 36/30 GG 26 73 1.0 -
cancer GA 25 49 1.4 0.75–2.8
AA 9 17 1.5 0.58–3.7
Breast cancer 31/26 GG 96 76 1.0 -
GA 84 40 1.7 1.0–2.7
AA 20 15 1.1 0.52–2.3
AML/MDS BLM
rs401549
31/30 AA 65 57 1.0 -
AG 75 51 1.3 0.77–2.1
GG 9 10 0.77 0.29–2.0
Malignant
melanoma
36/30 AA 62 57 1.0 -
AG 90 51 1.6 0.98–2.7
GG 16 10 1.5 0.61–3.5
Bladder 37/30 AA 26 64 1.0 -
cancer AG 24 67 0.90 0.47–1.7
GG 10 8 3.1 1.1–8.7
Breast cancer 34/33 AA 87 58 1.0 -
AG 94 61 1.0 0.65–1.6
GG 19 12 1.1 0.48–2.4
AML/MDS BLM
rs2532105
16/12 CC 103 90 1.0 -
CT+TTe 46 27 1.4 0.83–2.5
Malignant
melanoma
18/12 CC 109 90 1.0 -
CT+TT 59 27 1.8 1.1–3.2
Bladder cancer 20/10 CC 40 111 1.0 -
CT+TT 20 28 2.1 1.0–4.2
Breast cancer 17/13 CC 133 104 1.0 -
CT+TT 67 27 2.0 1.2–3.3
a Observe that the control group for AML/MDS (acute myeloid leukemia/myelodsyplastic syndromes) and malignant melanoma case groups was the 
same. Logistic regression, adjusted for age and sex. Statistically significant associations (p ≤ 0.05) are denoted in bold.
bAccession number for polymorphisms in the SNP database of National Centre of Biotechnology Information, http://www.ncbi.nlm.nih.gov/sites/
entrez?db=snp
c Reference category.
d For rs1563634, the reference category was changed to the variant allele in order to display cancer risk increment, and the risk allele frequency 
denotes thus the more common allele.
e Due to low variant allelic frequencies, the variant genotypes were merged.BMC Cancer 2009, 9:140 http://www.biomedcentral.com/1471-2407/9/140
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selected SNPs were in HWE in the breast cancer control
group as well (data not shown). The results from the ini-
tial screening of all SNPs and their association with AML/
MDS, malignant melanoma, and bladder cancer, are
shown in Additional file 1. Few statistically significant
findings were obtained when the tumour types were ana-
lysed separately. The SNP rs296887 (RMI1) was signifi-
cantly associated with increased cancer risks for AML/
MDS, as well as for malignant melanoma, but not with
risk for bladder cancer. In TOP3A, rs12945597 was associ-
ated with increased risk for AML/MDS and malignant
melanoma, and showed a non-significantly increased risk
for bladder cancer. In BLM, rs401549 was associated with
significantly increased risk for bladder cancer and a non-
significantly increased risk for malignant melanoma.
Rs2532105 (BLM) showed increased risk for malignant
melanoma and bladder cancer, and a non-significant risk
increment for AML/MDS. In AML/MDS, rs393974 (BLM)
and rs6496724 (BLM) were also significantly associated
with cancer risk.
For further analysis of breast cancer, rs12945597 in
TOP3A, rs401549, and rs2532105 in BLM were selected,
as well as rs1563634 in TOP3A, which showed similar
non-significant protective effects in all three cancer forms
for the variant homozygous carriers. For rs1563634, the
reference category was in the subsequent analyses
changed to the variant homozygotes in order to display
cancer risk increment. The rs12945597 in TOP3A  and
rs2532105 in BLM (Table 2) was significantly associated
with increased breast cancer risk. Dual-polymorphisms
Table 3: Cancer risk estimates for gene-gene combinations of A) 
rs12945597 (TOP3A) and rs2532105 (BLM) and B) rs1563634 
(TOP3A) and rs2532105 (BLM) in different cancer forms.a
IIIA. rs12945597+rs2532105
Genotype OR 95% CI
AML/MDS GG+CC 1.0 -
GG+T- 1.4 0.61–3.0
A-+CC 1.6 0.89–2.8
A-+T- 2.4 1.1–5.4
Malignant melanoma GG+CC 1.0 -
A-+CC 1.7 0.98–3.0
GG+T- 2.5 1.2–5.2
A-+T- 2.4 1.1–5.4
Bladder cancer GG+CC 1.0 -
A-+CC 1.4 0.68–2.9
GG+T- 2.1 0.74–6.1
A-+T- 3.0 1.1–7.7
Breast cancer GG+CC 1.0 -
A-+CC 1.5 0.92–2.6
GG+T- 2.0 1.0–4.1
A-+T- 3.0 1.4–6.4
IIIB. rs1563634b+rs2532105
Genotype OR 95% CI
AML/MDS AA+CC 1.0 -
AA+T- 0.48 0.087–2.7
G-+CC 1.1 0.39–3.1
G-+T- 1.9 0.62–5.8
Malignant melanoma AA+CC 1.0 -
AA+T- 0.48 0.089–2.6
G-+CC 1.1 0.41–3.1
G-+T- 2.5 0.84–7.4
Bladder cancer AA+CC 1.0 -
AA+T- 1.7 0.12–23
G-+CC 3.0 0.64–14
G-+T- 6.5 1.3–33
Breast cancer AA+CC 1.0 -
G-+CC 2.8 1.1–7.2
AA+T- 12 2.1–70
G-+T- 4.6 1.7–13
a Statistically significant associations (p ≤ 0.05) are denoted in bold. 
The analyses were adjusted for age and sex.
b For rs1563634, the reference category was changed to the variant 
allele in order to display cancer risk increment.
Table 4: Association of polymorphisms in TOP3A and BLM and 
risk of cancer (all cancer cases and all controls combined).a
SNP Genotype OR 95% CI FPRP 0.1b FPRP 0.01
rs1563634c AA 1.0 - -
(TOP3A) AG 1.7 1.1–2.6 0.48 0.92
GG 1.8 1.1–2.8 0.29 0.84
rs12945597 GG 1.0 - - -
(TOP3A) AG 1.5 1.1–1.9 0.014 0.13
AA 1.6 1.0–2.5 0.36 0.89
rs401549 AA 1.0 - - -
(BLM) AG 1.2 0.89–1.5 - -
GG 1.3 0.82–2.2 - -
rs2532105 CC 1.0 - - -
(BLM) CT+TT 1.8 1.5–2.5 0.029 0.27
a Statistically significant associations (p ≤ 0.05) are denoted in bold. 
The analyses were adjusted for age and sex.
b FPRP is only calculated for significant p-values.
c For rs1563634, the reference category was changed to the variant 
allele in order to display cancer risk increment.
Table 5: Gene-gene associations of polymorphisms in TOP3A and 
BLM and risk of cancer (all cancer cases and all controls 
combined).a
Polymorphisms Genotype OR 95% CI
rs12945597+rs2532105 GG+CC 1.0 -
A-+CC 1.6 1.2–2.1
GG+T- 2.0 1.3–3.1
A-+T- 2.7 1.8–4.3
rs1563634+rs2532105 AA+CC 1.0 -
G-+CC 1.9 1.1–3.2
AA+T- 2.0 0.85–4.
G-+T- 3.5 2.0–6.3
a Statistically significant associations (p ≤ 0.05) are denoted in bold. 
The analyses were adjusted for age and sex.BMC Cancer 2009, 9:140 http://www.biomedcentral.com/1471-2407/9/140
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analyses (in two different genes) were performed for all
cancer forms for the three SNPs showing main genetic
effects (Table 3). An allele-dosage effect was found for the
combination rs12945597 (TOP3A) and rs2532105 (BLM)
for AML/MDS, bladder and breast cancer, where carriers
with two variant alleles displayed the highest risks (Table
3A).
Based on these results, we combined all cases (N = 584)
and controls (N = 406), respectively and performed asso-
ciation analyses. The cases and controls showed a similar
distribution in age (cases median age = 65 years, controls
= 64 years), but differed for sex (63% women among cases
and 54% women among controls). For rs1563634,
rs12945597, and rs2532105, a significantly increased risk
for developing cancer was found (Table 4). The highest
risk was found for the combination of rs1563634 in
TOP3A and rs2532105 in BLM (OR = 3.5, 95% CI 2.0–
6.3; Table 5). We also performed a three-polymorphism
combination analysis for TOP3A  rs1563634 and
rs12945597, and BLM rs2532105 and found an OR = 3.8,
95% CI 2.0–7.3, for carriers of three variant alleles.
The impact of age on the associations between genetic
markers of the BLM-complex and cancer risk was evalu-
ated. For the two polymorphisms in TOP3A a stronger
effect was found among elderly individuals (rs1563634
GG carriers ≥ 65 years OR = 2.2 95% CI 1.2–4.0, <65 years
OR = 1.4 95% CI 0.73–2.7; rs12945597 AA carriers ≥ 65
years OR = 2.3 95% CI 1.2–4.4, <65 years OR = 1.1 95%CI
0.58–2.0). No such effect could be detected for the two
variants analysed in BLM (data not shown).
We evaluated the significance of the findings for all cancer
cases and controls combined by using FPRP analysis
(Table 4). At high prior probability (set as 0.1) all statisti-
cally significant findings demonstrated a low probability
for false positive results. However, at a lower prior proba-
bility (0.01), only the TOP3A rs12945597 (heterozygote)
and BLM rs2532105 displayed a FPRP value < 0.5.
The bioinformatics analyses revealed that TOP3A
rs1563634 is situated in a CpG island about 700 base
pairs upstream to the start codon in TOP3A. TOP3A
rs12945597 is located approximately 5 Kbp downstream
the coding region. BLM rs401549 and rs2532105 are situ-
ated in intron 21 of the gene.
Discussion
The present study shows that individuals carrying genetic
variants of the BLM-TOP3A-RMI1 complex have an
increased risk of AML/MDS, malignant melanoma, blad-
der and breast cancer. The strongest genetic risk marker
was found in BLM, i.e., the variant allele of rs2532105,
which showed a statistically significantly increased risk for
three out of four cancer forms analyzed. By considering
two polymorphisms a stronger association was obtained,
but there were no indications of a multiplicative interac-
tion between genetic variants at different gene loci.
These data suggests that some polymorphisms in the BLM
complex are general cancer susceptibility markers and that
the homologous recombination system may be involved
in neoplastic transformation of several cell types. Our
finding is in line with the observation that individuals
with Blooms syndrome carrying mutations in BLM, essen-
tial for the homologous recombination complex, show
elevated risk for various cancer types. There are increasing
amount of evidence that homologous recombination gen-
erates loss of heterozygosity in various cancer types e.g.
acute myeloid leukemias, follicular lymphomas, breast
cancer, bladder cancer, gastrointestinal stromal tumors
and Barrett's oesophagus [15-20]. A recent study have also
shown the importance of the BLM-TOP3A-RMI1 for the
maintenance of the genome stability by faithful chromo-
some segregation and prevention of anaphase
bridges[21], a cytogenetic aberration found in several
types of neoplastic cells. In a recent investigation, we
found a more pronounced effect among elderly individu-
als for the Ser455Asn polymorphism in RMI1  [7]. We
found a similar pattern in this study for the two polymor-
phisms in TOP3A, possibly reflecting the finding that
mitotic recombination increases with age [22] and, hypo-
thetically, that protein variants involved in this process
has a larger influence when the body burden of mitotic
recombination increases.
The effect of the polymorphisms remains to be clarified.
None of the three rs1563634, rs12945597, and
rs2532105 result in non-synonymous exchanges or are in
LD with non-synonymous SNPs (data not shown). How-
ever, rs1563634 is positioned in a CpG island upstream to
the TOP3A gene. The SNP does not in itself introduce or
remove an extra CpG, but CpG regions tend to be associ-
ated with gene promoter regions and hence the polymor-
phism may affect transcriptional activity [23].
There are several limitations with the study. One problem
is that smaller case-control studies may lead to spurious
association and it is important to stress that our findings
need to be confirmed in other case-control studies. For
bladder cancer, the drop out in genotype data/assay was
fairly high and these data should thus be cautiously inter-
preted. The characteristics of the control groups differed;
they were selected in different ways during different time
frames, showed varying degree of participation, and var-
ied in sex and age distribution. However, allelic frequen-
cies in the different control groups were similar,
indicating that the observed frequencies are good esti-
mates of the true frequency in this region of Sweden. OnBMC Cancer 2009, 9:140 http://www.biomedcentral.com/1471-2407/9/140
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the other hand, there were different allelic distributions
for the SNPs in the different cancer forms. Different repair
pathways are important for different cancer forms, but
based on our results on each cancer form, homologous
recombination may be important in several cancer types.
However, the genetic influence is not expected to be
exactly the same for the different cancers and therefore,
the allelic frequencies may differ. Since the separate anal-
ysis for each cancer points at influence of the BLM system,
it was considered acceptable to combine all cases and con-
trols, despite the fact that the cancer forms in this study are
very different in etiology, and genetic heterogeneity is
present in different tumour forms. When the cases from
all cancer forms and the different control groups were
combined in one analysis, the case and control groups dif-
fered somewhat in sex, but were very similar in age distri-
bution. Still, it should be noted that apart from factors as
age and sex, we have not evaluated cancer-specific risk fac-
tors, which could influence the associations between
SNPs in the BLM complex and cancer risk.
We conducted a false-positive report probability (FPRP)
analyses in order to assess the risk of false positives. The
prior probabilities were considered relatively high (0.1)
due to the impact of mutations in BLM for cancer risk in
Bloom syndrome patients and the functional relevance of
the TOP3A for the BLM complex. However, since there
was little evidence for functional effect for the SNPs ana-
lysed, based on bioinformatics analysis, the prior proba-
bility of 0.01 was also taken into consideration. With this
cut-off, only the TOP3A rs12945597 and BLM rs2532105
remained as significant findings. Thus, the other observed
associations in this study have to be validated in a larger
cohort.
There are very few other studies of polymorphisms of the
BLM-complex and cancer risk. As mentioned, we have pre-
viously studied the Ser455Asn polymorphism in RMI1
and found an association between increased risk of AML/
MDS and malignant melanoma for variant carriers. In this
study, we analysed the SNP rs296887, which is linked to
RMI1 Ser455Asn and found a similar but weaker effect for
AML/MDS and malignant melanoma but no effect in
bladder cancer. Other studies have analyzed BLM
Thr298Met and small cell lung carcinoma risk [24] and
BLM Pro868Leu and familial breast cancer [25], but none
of these polymorphisms showed any association with
cancer risk. However, there are several studies on other
genes that are required for homologous recombination
repair, i.e. RAD51, XRCC2 and XRCC3. The RAD51-135
(G/C) variant allele has been associated with increased
risk of AML and this relation was most pronounced for
AML associated with a previous history of treatment with
chemo- or radiotherapy [26-29]. The results for the
XRCC3 Thr241Met variant have so far been not been con-
clusive: variant carriers was found to have increased risk of
bladder and breast cancer and malignant melanoma [30-
32], whereas in a previous study of ours no association
with this marker and bladder cancer was demonstrated
[8]. In one meta-analysis, there was no significant associ-
ations between XRCC3 Thr241Met and cancer of the blad-
der, breast, lung or skin [33], but in another meta-analysis
the Met/Met genotype showed a small cancer risk with the
strongest effect found for breast cancer [34]. Also for the
XRCC2 gene the results have been contradictory, the vari-
ant allele of Arg188His has been associated with increased
cancer risk for breast and pharyngeal cancer and smoking-
related pancreatic cancer [35-37], whereas for epithelial
ovarian cancer there was no effect or a reduced
risk[38,39].
Conclusion
Our data indicate that variants of the BLM-TOP3A-RMI1
recombination complex, has an impact on cancer risk.
Since the SNPs are common among our subjects with
AML/MDS, malignant melanoma, bladder and breast can-
cer, even the moderate increase in risk observed in this
study may be associated with a considerable impact. How-
ever, the results need to be confirmed in subsequent stud-
ies.
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